Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Identifieur interne : 000C83 ( PascalFrancis/Corpus ); précédent : 000C82; suivant : 000C84Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Auteurs : Christopher G. Goetz ; Werner Poewe ; Olivier Rascol ; Cristina SampaioSource :
- Movement disorders [ 0885-3185 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non-efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 05-0281338 INIST |
|---|---|
| ET : | Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| AU : | GOETZ (Christopher G.); POEWE (Werner); RASCOL (Olivier); SAMPAIO (Cristina) |
| AF : | Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center/Chicago, Illinois/Etats-Unis (1 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (2 aut.); Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital/Toulouse/France (3 aut.); Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa/Lisbon/Portugal (4 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 5; Pp. 523-539; Bibl. 47 ref. |
| LA : | Anglais |
| EA : | The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non-efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner. |
| CC : | 002B17; 002B17G; 002B17A03 |
| FD : | Système nerveux pathologie; Parkinson maladie; Chirurgie; Traitement; Médecine factuelle; Lévodopa; Stimulant dopaminergique; Amine oxidase (flavin-containing); Amantadine; Stimulation cérébrale profonde |
| FG : | Oxidoreductases; Enzyme; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie |
| ED : | Nervous system diseases; Parkinson disease; Surgery; Treatment; Evidence-based medicine; Levodopa; Dopamine agonist; Amine oxidase (flavin-containing); Amantadine; Deep brain stimulation |
| EG : | Oxidoreductases; Enzyme; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
| SD : | Sistema nervioso patología; Parkinson enfermedad; Cirugía; Tratamiento; Medicina basada en pruebas; Levodopa; Estimulante dopaminérgico; Amine oxidase (flavin-containing); Amantadina |
| LO : | INIST-20953.354000124690200010 |
| ID : | 05-0281338 |
Links to Exploration step
Pascal:05-0281338Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><inist:fA14 i1="03"><s1>Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><inist:fA14 i1="04"><s1>Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0281338</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0281338 INIST</idno><idno type="RBID">Pascal:05-0281338</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><inist:fA14 i1="03"><s1>Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><inist:fA14 i1="04"><s1>Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term><term>Amine oxidase (flavin-containing)</term><term>Deep brain stimulation</term><term>Dopamine agonist</term><term>Evidence-based medicine</term><term>Levodopa</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Surgery</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Chirurgie</term><term>Traitement</term><term>Médecine factuelle</term><term>Lévodopa</term><term>Stimulant dopaminergique</term><term>Amine oxidase (flavin-containing)</term><term>Amantadine</term><term>Stimulation cérébrale profonde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non-efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>20</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</s1></fA08><fA11 i1="01" i2="1"><s1>GOETZ (Christopher G.)</s1></fA11><fA11 i1="02" i2="1"><s1>POEWE (Werner)</s1></fA11><fA11 i1="03" i2="1"><s1>RASCOL (Olivier)</s1></fA11><fA11 i1="04" i2="1"><s1>SAMPAIO (Cristina)</s1></fA11><fA14 i1="01"><s1>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>4 aut.</sZ></fA14><fA20><s1>523-539</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000124690200010</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>47 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0281338</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non-efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B17A03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Chirurgie</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Surgery</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Cirugía</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Médecine factuelle</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Evidence-based medicine</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Medicina basada en pruebas</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Dopamine agonist</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>14</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Amantadine</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Amantadine</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Amantadina</s0><s2>NK</s2><s2>FR</s2><s5>15</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Stimulation cérébrale profonde</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Deep brain stimulation</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>199</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 05-0281338 INIST</NO><ET>Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004</ET><AU>GOETZ (Christopher G.); POEWE (Werner); RASCOL (Olivier); SAMPAIO (Cristina)</AU><AF>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center/Chicago, Illinois/Etats-Unis (1 aut.); Department of Neurology, Innsbruck Medical University/Innsbruck/Autriche (2 aut.); Department of Pharmacology, Clinical Investigation Center, Toulouse University Hospital/Toulouse/France (3 aut.); Department of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa/Lisbon/Portugal (4 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 5; Pp. 523-539; Bibl. 47 ref.</SO><LA>Anglais</LA><EA>The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non-efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</EA><CC>002B17; 002B17G; 002B17A03</CC><FD>Système nerveux pathologie; Parkinson maladie; Chirurgie; Traitement; Médecine factuelle; Lévodopa; Stimulant dopaminergique; Amine oxidase (flavin-containing); Amantadine; Stimulation cérébrale profonde</FD><FG>Oxidoreductases; Enzyme; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG><ED>Nervous system diseases; Parkinson disease; Surgery; Treatment; Evidence-based medicine; Levodopa; Dopamine agonist; Amine oxidase (flavin-containing); Amantadine; Deep brain stimulation</ED><EG>Oxidoreductases; Enzyme; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG><SD>Sistema nervioso patología; Parkinson enfermedad; Cirugía; Tratamiento; Medicina basada en pruebas; Levodopa; Estimulante dopaminérgico; Amine oxidase (flavin-containing); Amantadina</SD><LO>INIST-20953.354000124690200010</LO><ID>05-0281338</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:05-0281338
|texte= Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
}}
| This area was generated with Dilib version V0.6.29. |  |